Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6319086
Reference Type
Journal Article
Title
[Ataxic neuropathy associated with disialosylated antibodies: description of new clinical and biochemical forms]
Author(s)
Delval, A; Stojkovic, T; de Sèze, J; Hurtevent, JF; Glowacki, F; Beaume, A; Destée, A; Vermersch, P
Year
2004
Is Peer Reviewed?
1
Journal
Revue Neurologique
ISSN:
0035-3787
Volume
160
Issue
10
Page Numbers
910-916
Language
French
PMID
15492717
DOI
10.1016/s0035-3787(04)71072-3
Web of Science Id
WOS:000224803600003
Abstract
INTRODUCTION:
Polyneuropathies associated with IgM monoclonal gammopathy were recently recognized. Antibodies can react with glycoproteins such as myelin associated glycoprotein (MAG), or gangliosides containing one sialosyl epitope such as GM1 or several sialosyl epitopes (polysialyted gangliosides) including GD2, GD3, GT1b, GT1a, GQ1b.
METHODS:
We report on three patients presenting oculomotor dysfunction, chronic sensitive ataxic polyneuropathy, high sedimentation rate, IgM monoclonal paraprotein of unknown signification and antidisialosyl IgM antibodies and for two of them cold agglutinins. Such features have been previously described under the acronym "CANOMAD" (chronic ataxic neuropathy with ophthalmoplegia, M protein, agglutination and disialosyl antibodies).
RESULTS:
One of the patients presents extramembranous glomerulopathy and severe motor disability associated with this syndrome. The pathophysiology of the glomerulopathy seems to be linked with the polyneuropathy. Patients were treated either by intravenous immunoglobulin, corticosteroids or cyclophosphamid. Response to treatment differs in the three cases and there is currently no consensus.
CONCLUSION:
Our study demonstrates that spectrum of polyneuropathy associated with monoclonal polyneuropathy may be larger than originally described.
Keywords
CANOMAD; glomerulonephritis; polyneuropathy; sensitive; motor
Tags
PFAS
•
Additional PFAS (formerly XAgency)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity